EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Relevance of mexiletine in the era of evolving antiarrhythmic therapy of ventricular arrhythmias

Nawar Alhourani, Julian Wolfes, Hilke Könemann, Christian Ellermann, Gerrit Frommeyer, Fatih Güner, Philipp Sebastian Lange, Florian Reinke, Julia Köbe, Lars Eckardt

Clinical Research in Cardiology · 2024-06 · 113 (6) · 791-800

DOI: 10.1007/s00392-024-02383-9 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Clinical Research in Cardiology, online erschienen am 14.02.2024. Verfasst von Nawar Alhourani und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology II: Electrophysiology, University Hospital Münster, Münster, Germany. nawar.alhourani@ukmuenster.de. Hauptthemen laut MEDLINE: Mexiletine, Anti-Arrhythmia Agents. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 81 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Universitätsklinikum Münster.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Despite impressive developments in the field of ventricular arrhythmias, there is still a relevant number of patients with ventricular arrhythmias who require antiarrhythmic drug therapy and may, e.g., in otherwise drug and/or ablation refractory situations, benefit from agents known for decades, such as mexiletine. Through its capability of blocking fast sodium channels in cardiomyocytes, it has played a minor to moderate antiarrhythmic role throughout the recent decades. Nevertheless, certain patients with structural heart disease suffering from drug-refractory, i.e., mainly amiodarone refractory ventricular arrhythmias, as well as those with selected forms of congenital long QT syndrome (LQTS) may nowadays still benefit from mexiletine. Here, we outline mexiletine’s cellular and clinical electrophysiological properties. In addition, the application of mexiletine may be accompanied by various potential side effects, e.g., nausea and tremor, and is limited by several drug-drug interactions. Thus, we shed light on the current therapeutic role of mexiletine for therapy of ventricular arrhythmias and discuss clinically relevant aspects of its indications based on current evidence. Graphical abstract

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MexiletineAnti-Arrhythmia AgentsHumansTachycardia, VentricularTreatment Outcome

Stichwörter der Autor:innen

Long QT syndromeMexiletineSodium channelSudden cardiac deathVentricular tachyarrhythmias

Substanzen

MexiletineAnti-Arrhythmia Agents

Autor:innen und Institutionen

  • Department of Cardiology II: Electrophysiology, University Hospital Münster, Münster, Germany. nawar.alhourani@ukmuenster.de.
  • Department of Cardiology II: Electrophysiology, University Hospital Münster, Münster, Germany.

Förderung

  • Universitätsklinikum Münster

Zitieren

APA

Alhourani, N., Wolfes, J., Könemann, H., Ellermann, C., Frommeyer, G., Güner, F., Lange, P. S., Reinke, F., Köbe, J., & Eckardt, L. (2024). Relevance of mexiletine in the era of evolving antiarrhythmic therapy of ventricular arrhythmias. Clinical Research in Cardiology, 113(6), 791-800. https://doi.org/10.1007/s00392-024-02383-9

Vancouver

Alhourani N, Wolfes J, Könemann H, Ellermann C, Frommeyer G, Güner F, et al. Relevance of mexiletine in the era of evolving antiarrhythmic therapy of ventricular arrhythmias. Clinical Research in Cardiology. 2024;113(6):791-800. doi:10.1007/s00392-024-02383-9

BibTeX
@article{Alhourani2024,
  author = {Alhourani, Nawar and Wolfes, Julian and Könemann, Hilke and Ellermann, Christian and Frommeyer, Gerrit and Güner, Fatih and Lange, Philipp Sebastian and Reinke, Florian and Köbe, Julia and Eckardt, Lars},
  title = {Relevance of mexiletine in the era of evolving antiarrhythmic therapy of ventricular arrhythmias},
  journal = {Clinical Research in Cardiology},
  year = {2024},
  volume = {113},
  number = {6},
  pages = {791--800},
  doi = {10.1007/s00392-024-02383-9}
}
Kostenlos starten →